Lipoprotein (a) in peripheral arterial occlusive disease

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Vascular Disease Research

Background:

• Elevated lipoprotein (a) [Lp(a)] levels are recognized as an atherogenic and thrombogenic risk factor for coronary heart disease.
• Peripheral arterial occlusive disease (PAOD) is often associated with altered lipid profiles.
• Understanding Lp(a) levels in PAOD is crucial for risk stratification and management.

Purpose of the Study:

• To evaluate lipoprotein (a) [Lp(a)] levels in patients with stage II peripheral arterial occlusive disease (PAOD).
• To compare Lp(a) levels between PAOD patients and a matched healthy control group.
• To investigate the association between Lp(a) levels and other lipid factors in PAOD.

Main Methods:

• A cohort of 45 patients with stage II PAOD was recruited.
• An age-, sex-, and BMI-matched healthy control group was included for comparison.
• Exclusion criteria targeted diseases or medications that could affect Lp(a) levels.
• Lipoprotein (a) [Lp(a)] and other lipid parameters were measured in both groups.

Main Results:

• Lipid profiles showed alterations consistent with PAOD in the patient group.
• Mean and median Lp(a) levels did not significantly differ between PAOD patients and controls.
• A significantly lower proportion of PAOD patients (20%) had Lp(a) levels < 10 mg/dl compared to controls (51%) (p < 0.05).

Conclusions:

• While overall Lp(a) levels may not differ significantly, PAOD patients are less likely to exhibit low Lp(a) levels compared to healthy individuals.
• These findings suggest a potential role for Lp(a) in the pathophysiology or progression of peripheral arterial occlusive disease.
• Further research is warranted to elucidate the specific relationship between Lp(a) and PAOD.